A Continuous Glucose Monitoring System (CGMS) is a medical device that tracks glucose levels in real time through a small wearable sensor placed under the skin. Unlike traditional fingerprick testing, which provides a single glucose reading at one moment, CGMS offers continuous data, showing trends, patterns, and alerts for high or low glucose levels —helping healthcare providers and patients make more informed, proactive treatment decisions.
Contact usOnce the CGM is applied to your arm, the sensor begins working beneath the skin.
The sensor contains biomaterials that react with glucose in the interstitial fluid. These reactions generate biochemical signals, which are detected and converted into glucose values every few minutes.
The transmitter then sends this data to your phone app or receiver.
Allowing you to view glucose trends, receive high and low alerts, and monitor changes throughout the day.
Note: Since glucose naturally moves from the bloodstream into the interstitial fluid, interstitial glucose readings closely reflect blood glucose levels.
The global diabetes epidemic and rising healthcare expenditure are accelerating demand for continuous monitoring solutions.
The number of adults living with diabetes has more than tripled since 2000, driven by aging populations, rising obesity rates, and increasingly sedentary lifestyles across both developed and developing nations.
Diabetes accounts for a significant and growing share of global healthcare spending, covering medications, devices, hospitalizations, and long-term complication management across all regions.
Without significant intervention, the number of adults with diabetes is projected to continue rising sharply, creating sustained long-term demand for advanced monitoring and management tools.
The CGM devices market reached an estimated USD 13.38 billion in 2025, with the US alone accounting for USD 5.6 billion, driven by strong reimbursement policies and growing Type 2 diabetes adoption.
The CGM market is projected to grow at a compound annual growth rate of 16.3% from 2026 to 2035, outpacing most other medical device segments and reflecting accelerating global adoption.
The global CGM devices market is forecast to nearly triple from 2025 levels, reaching USD 41.41 billion by 2033 as non-invasive technologies and AI-powered analytics drive next-generation adoption.
Despite advances in treatment, only about half of individuals with diabetes achieve recommended glycemic targets —highlighting the urgent need for better continuous monitoring solutions.
Diabetes prevalence continues to rise at approximately 4.2% annually in developing regions, driven by urbanization, dietary changes, and aging populations —expanding the addressable CGM market.
The number of adults living with diabetes has more than tripled since 2000, driven by aging populations, rising obesity rates, and increasingly sedentary lifestyles across both developed and developing nations.
Diabetes accounts for a significant and growing share of global healthcare spending, covering medications, devices, hospitalizations, and long-term complication management across all regions.
Without significant intervention, the number of adults with diabetes is projected to continue rising sharply, creating sustained long-term demand for advanced monitoring and management tools.
The CGM devices market reached an estimated USD 13.38 billion in 2025, with the US alone accounting for USD 5.6 billion, driven by strong reimbursement policies and growing Type 2 diabetes adoption.
The CGM market is projected to grow at a compound annual growth rate of 16.3% from 2026 to 2035, outpacing most other medical device segments and reflecting accelerating global adoption.
The global CGM devices market is forecast to nearly triple from 2025 levels, reaching USD 41.41 billion by 2033 as non-invasive technologies and AI-powered analytics drive next-generation adoption.
Despite advances in treatment, only about half of individuals with diabetes achieve recommended glycemic targets —highlighting the urgent need for better continuous monitoring solutions.
Diabetes prevalence continues to rise at approximately 4.2% annually in developing regions, driven by urbanization, dietary changes, and aging populations —expanding the addressable CGM market.
Adding CGM to your healthcare portfolio creates clinical and commercial value across multiple dimensions.
As CGM adoption grows, offering CGM solutions helps your business stay competitive in an evolving diabetes care market and meet changing customer expectations.
Add CGM to your existing diabetes, diagnostic, or chronic care portfolio, creating extra value for clients and new opportunities for growth.
CGM systems rely on disposable sensors that are typically replaced every 14 days, allowing you to benefit from continuous repeat orders rather than one-time purchases.
CGM gives you trend-based glucose insights instead of isolated measurements, helping doctors and healthcare teams make informed treatment decisions.
You can reduce reliance on scattered glucose checks and integrate continuous glucose data into digital health workflows, improving patient monitoring beyond in-person visits.
CGM allows care teams to monitor patients' glucose changes continuously, helping identify abnormal patterns before they become more serious.
Choose the partnership model that fits your business stage and capabilities.
Partially assembled CGM kits that allow you to complete local assembly, packaging, and labeling under your own brand. Includes regulatory documentation support to help you navigate country-specific compliance requirements.
Launch your own branded CGM with full system manufacturing handled by EverChek. From sensor production to final packaging, we build the complete product to your specifications while you focus on market development.
Become an authorized distributor of EverChek CGM products in your region. No assembly lines or clean rooms needed —simply leverage our ready-to-market products and your local sales network.
EverChek brings end-to-end CGM expertise — from R&D to regulatory compliance — to accelerate your market entry.
We develop our CGM technology in-house鈥攆rom sensor design to algorithms and full system integration. This gives you direct technical support, better product control, and a more stable supply chain.
Our production facilities are built for scalable manufacturing with consistent quality standards. You get reliable supply, predictable lead times, and stable product performance.
Beyond hardware, we provide both patient and physician applications. You offer a complete CGM solution with connected data, monitoring, and clinical visibility.
We support partners with registration preparation, technical documentation, and compliance requirements to simplify local market entry.
Whether you need SKD, OEM, distribution, or a customized partnership structure, we adapt based on your market goals, regulatory needs, and business stage.
We work as a long-term partner, supporting your growth as your business expands into new markets and larger opportunities.